Philip Morris International Inc. (PM)

Executive Summary

This report refreshes T&T Capital Management’s May 2026 research on Philip Morris International following the company’s first-quarter 2026 results and the single most important regulatory event in its history: in January 2026 the U.S. FDA granted ZYN the first-ever marketing authorizations for nicotine pouches, clearing twenty products across ten flavors through the Premarket Tobacco Product Application (PMTA) pathway. That decision removed the existential overhang that capped our prior bear case and converted ZYN from a regulatory question mark into an FDA-blessed, share-leading growth engine.

What’s Inside The Full Report

• 15-year financial summary table — revenue, net income, GAAP & adjusted EPS
• Valuation framework — current multiples vs. 5-year historical range
• Peer comparison table — multiples, margins, balance-sheet metrics
• Base case, bull case, bear case price targets with explicit math
• Competitive position and economic moat analysis
• Management and capital allocation track record
• Balance sheet review — leverage, credit ratings, distribution coverage
• Insider activity — recent open-market buys / sells with interpretation
• Strategic acquisitions and divestitures history
• Sell-side consensus and where TTCM differs
• Detailed risk factors specific to the name
• Bull case and forward catalysts to watch
• TTCM rating with explicit ADD / TRIM price triggers